



## Ying Li

*Beijing*

---

+86 10 8524 5882  
ying.li@hankunlaw.com

### **PRACTICE AREAS**

- Intellectual property

### **PROFESSIONAL EXPERIENCE**

Dr. Li's expertise covers patent prosecution, invalidation and litigation, patent searches, patent transactions, and other IP-related counseling. She has extensive experience in providing a range of legal services to both domestic and multinational clients and has assisted many industry-leading clients in obtaining patents in China. Prior to joining Han Kun, Dr. Li practiced for 16 years with CCPIT Patent and Trademark Law Office, where she was a group leader for 9 years.

Dr. Li's practice covers a variety of legal services, such as patent mining, drafting and responding to office actions, prior art searches, freedom-to-operate (FTO) searches and analysis, and consulting. Additionally, Dr. Li has extensive experience using the STN database in FTO searches related to small molecule drugs and biological macro-molecules such as proteins and nucleic acids. Dr. Li has successfully represented many clients before the China National IP Administration and the courts in various patent invalidation and administrative litigation cases. She has taken charge of many large and complex cases and is widely recognized and trusted by her clients for obtaining excellent results and for her excellent communication skills.

### **EDUCATION**

Dr. Li received a Ph.D. in Microbiology and Biochemical Pharmacology in 2005 from the Institute of Medical Biotechnology, Peking Union Medical College. Prior to that, she received both her bachelor's degree and MSc in Microbiology and Biochemical Pharmacology from Jilin University and Shenyang Pharmaceutical University as part of a joint program in 1999 and 2002, respectively.

### **QUALIFICATIONS**

Member of the PRC Patent Bar  
Member of the PRC Bar

### **HONORS AND AWARDS**

She was selected as The 2017-2018 Beijing Excellent Patent Attorney by the Beijing Patent Attorneys Association.

### **SOCIAL RESPONSIBILITIES**

Member of the Pharmaceutical Professional Committee of the China Patent Protection Association

Expert of the Genetic Resources Group of the ICC China Commission on Intellectual Property  
Member of the Japan Intellectual Property Association

## **PUBLICATIONS**

Patent portfolio management of small pharmaceutical molecules, July 25, 2022, IPLEAD

Make plans first: patent portfolio management strategies for medicines, July 6, 2022, IPLEAD

The value of FTO in investment and financing in the field of biomedicine, May 6, 2022, IPLEAD

The Trends & Developments 2022 – China, March 25, 2022, China's T&D section for the Chambers Life Sciences 2022 Guide

China's drug-patent linkage system has landed, June 16, 2021, IPSTARS.COM

What is IP Due Diligence and FTO? December 17, 2021, Han Kun Insights

IP issues in IPO of the Hong Kong Stock Exchange 18A, October 9, 2021, Han Kun Insights

Quick Review "Implementation Measures for the Early Resolution Mechanism of Drug Patent Link-age (Trial)", July 4, 2021, Han Kun Insights

A look at intellectual property due diligence in pharmaceuticals, July 2, 2021, IPLEAD

Legal risks and compliance solutions for human genetic resources issues, May 21, 2021, Han Kun Insights

The impact of functional features on the scope of protection of claims in the patent prosecution and invalidation procedures and infringement determination in China, AIPPI (2021) Vol. 66, No.3

Interpretation of the "Implementation Measures for the Early Resolution Mechanism of Drug Patent Disputes (Trial) (Draft for Comment)", September 16, 2020, China IP Magazine

Cloud hearing: A new balance between procedural convenience and procedural fairness, August 5, 2020, China IP News

How to deal with internal and external IP risks for a pharmaceutical company? May 3, 2018, IPR Dai-ly

The drug-patent linkage system is coming, how should the generic drug side respond? November 29, 2017, IPR Daily

Latest Examination Trends on insufficient disclosure issues of Chemical and Pharmaceutical Inventions: A New Hope, November 2014, Lexology

## **WORKING LANGUAGES**

Chinese, English, Japanese



## 李英

北京

+86 10 8524 5882  
ying.li@hankunlaw.com

### 业务领域

- 知识产权

### 工作经历

李英博士的专长包括专利申请、无效和诉讼、专利检索、专利交易以及其他与知识产权相关的咨询。她在为国内和跨国客户提供法律服务方面拥有丰富的经验，曾协助许多行业领先的客户在中国获得专利。在加入汉坤之前，李博士曾在中国国际贸易促进委员会专利商标事务所工作 16 年，其中有 9 年担任团队负责人。

李博士的业务涵盖专利挖掘和布局、撰写申请、答复审查意见、现有技术检索、FTO 检索和分析等。她在用 STN 等数据库进行化学小分子药物和包括核酸以及蛋白质在内的生物大分子的检索方面经验丰富。她曾代表许多客户在国家知识产权局和各地法院审理的多起专利无效和行政诉讼案件中取得过胜利成果。她多次在大型复杂案件中担任主要办案人和组织者，凭借优秀的诉讼结果和出色的沟通能力获得了客户的广泛认可和信任。

### 教育背景

李英博士于 2005 年获得协和医科大学生物技术研究所微生物与生化药学博士学位，在此之前，她分别于 1999 年和 2002 年获得吉林大学和沈阳药科大学微生物与生化药学本科和硕士学位。

### 执业资格

中华人民共和国专利代理人执业资格  
中华人民共和国律师执业资格

### 荣誉与奖项

2019 年被北京专利代理人协会评为 2017-2018 年度北京市优秀专利代理人。

### 社会任职

中国专利保护协会医药专业委员会委员  
国际商会知识产权委员会遗传资源行动组专家成员  
一般社团法人日本知识产权协会 JIPA 成员

### 最近出版物

公开讲演及出版作品  
应健识局和中国医药工业信息中心邀请，围绕药品专利布局如何做好攻和防，于 2022 年 5 月

17日以“从药品专利到期看企业专利布局”进行线上直播  
作为主题演讲嘉宾，于2021年11月11日在上海应国方资本邀请，在2021年长三角创新生物技术行业闭门会议上就“国内生物技术公司面临的专利挑战”发表演讲  
在2021年9月25日-27日在苏州金鸡湖会议中心举办的第六届中国医药创新与投资大会，参加“科创板助力生物医药产业创新发展”的论坛主题讨论，并就“医疗器械和医药领域的IP风险”等热点问题探讨  
管中窥豹-小分子化学药物的专利布局，2022年7月25日，知产力  
谋定而后动，知止而有得：谈药品的专利布局，2022年7月6日，知产力  
FTO在生物医药领域投融资中的价值，2022年5月6日，知产力  
The Trends & Developments 2022 – China, March 25th, 2022, China's T&D section for Chambers Life Sciences 2022 Guide  
涉军企业系列解读-投融资项目知识产权尽职调查，2021年12月30日，汉坤观点  
什么是IP DD和FTO？从一个骰子说开去……，2021年12月17日，开卷有益  
汉坤大健康圆桌π：港股18A上市（一）-IPO申报材料中的IP问题和IP风险因素，2021年10月9日，汉坤观点  
沉浸式全览-医药合作开发的常见模式与市场观察，2021年9月23日，汉坤医药专题（六）  
靴子终落地-快评《药品专利链接早期解决机制实施办法（试行）》，2021年7月4日，汉坤观点  
浪淘沙-再看医药领域的知识产权尽职调查，2021年7月2日，知产力  
China's drug-patent linkage system has landed, 16 June 2021, IPSTARS.COM  
医疗健康领域的合规之路-有关人类遗产资源信息管理的法律风险和化解之道，2021年5月21日，汉坤观点  
论功能性特征限定在中国的授权确权程序中以及侵权判定中对权利要求保护范围的影响(The impact of functional features on the scope of protection of claims in the patent prosecution and invalidation procedures and infringement determination in China), AIPPI (2021) Vol.66, No.3  
对《药品专利纠纷早期解决机制实施办法（试行）（征求意见稿）》的解读，2020年9月16日，中国知识产权杂志  
云开庭：程序便利与程序公正的新平衡，2020年8月5日，中国知识产权报  
如何应对内忧型和外患型的专利风险及其防范？2018年5月3日，IPR Daily  
药品专利链接制度乍现，仿制药方如何应对？2017年11月29日，IPR Daily  
化学医药发明充分公开审查的最新趋势：新的希望，2014年11月，Lexology 杂志

## 工作语言

中文、英文、日语